Aurobindo may take its injectable unit public

Aurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previously hampered by valuation issues with private equity, the process faces new hurdles due to USFDA observations. Eugia aims to reach $600 million in revenue this fiscal year. Regulatory issues at Unit-3 remain a concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NEiOlVA
via IFTTT